Phase III study of ribociclib (LEE011) plus fulvestrant for the treatment of postmenopausal patients with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2–) advanced breast cancer (aBC) who have received no or only one line of prior endocrine treatment (ET): MONALEESA-3.
Copyright policy )Phase III study of ribociclib (LEE011) plus fulvestrant for the treatment of postmenopausal patients with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2–) advanced breast cancer (aBC) who have received no or only one line of prior endocrine treatment (ET): MONALEESA-3.
TPS624Background: Inhibition of the cyclin D–cyclin dependent kinase (CDK)4/6–retinoblastoma pathway may overcome ET resistance and enhance the efficacy of existing ET regimens in HR+, HER2– aBC. Combination of the CDK4/6 inhibitor ribociclib (LEE) with fulvestrant (FUL) has demonstrated potent tumor regressions in preclinical HR+ breast cancer (BC) models (O’Brien et al. Cancer Res 2014;74:Abstr 4756). Methods: In this phase III, double-blind study (NCT02422615), postmenopausal patients with HR+, HER2– aBC (N≈660) will be randomized 2:1 to oral LEE (600 mg QD on Days 1–21 of each 28-day cycle) + FUL (500 mg intramuscularly on Days 1 and 15 of Cycle 1 and Day 1 of each cycle thereafter; Arm A) or placebo + FUL (Arm B). Randomization is stratified by presence of lung or liver metastases and prior ET. Patients may have newly diagnosed aBC that is treatment-naive, relapsed BC that has progressed at any time during/after (neo)adjuvant ET with no treatment for metastatic disease, relapsed BC that has progresse...
- Duke University Hospital United States
- University of Liège Belgium
- New York University United States
- Duke University United States
- New York University Langone Medical Center United States
Oncology, oncology, Oncologie, Human health sciences, Sciences de la santé humaine
Oncology, oncology, Oncologie, Human health sciences, Sciences de la santé humaine
selected citations These citations are derived from selected sources.This is an alternative to the "Influence" indicator, which also reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically).10 popularity This indicator reflects the "current" impact/attention (the "hype") of an article in the research community at large, based on the underlying citation network.Average influence This indicator reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically).Average impulse This indicator reflects the initial momentum of an article directly after its publication, based on the underlying citation network.Top 10%
Citations provided by BIP!Popularity provided by BIP!